. Author manuscript; available in PMC: 2021 Aug 20.

Published in final edited form as: Clin Genitourin Cancer. 2021 Mar 16;19(4):362–368. doi: 10.1016/j.clgc.2021.03.007

Table 4.

Multivariate overall survival (OS) analysis among patients who received trimodality therapy (TMT) with or without neoadjuvant chemo (NAC) for muscle invasive bladder sensitivity analysis using overall survival defined from start date of radiation.

Variable	Level	N	Hazard Ratio (95% CI)	P-value*

Cohort	TMT	2087	-
	NAC+TMT	458	0.97 (0.86–1.10)	0.618

The estimated stratified treatment effect was controlled by: age, comorbidity, facility, income, education, insurance, race, region, T stage, and year.